Fecal short chain fatty acids and urinary 3-indoxyl sulfate do not discriminate between patients with Crohn´s disease and ulcerative colitis and are not of diagnostic utility for predicting disease severity

URN zum Zitieren dieses Dokuments:

urn:nbn:de:bvb:355-epub-547884 Copy

DOI zum Zitieren dieses Dokuments:

10.5283/epub.54788 Copy

Tews, Hauke Christian ; Elger, Tanja ; Gunawan, Stefan ; Fererberger, Tanja ; Sommersberger, Stefanie ; Loibl, Johanna ; Huss, Muriel ; Liebisch, Gerhard ; Müller, Martina ; Kandulski, Arne ; Buechler, Christa

Lizenz: Creative Commons Namensnennung 4.0 International PDF - Veröffentlichte Version (1MB)

Veröffentlichungsdatum dieses Volltextes: 05 Okt 2023 12:00

---

Alternative Links zum Volltext:DOIVerlag

---

---

Details

Dokumentenart:	Artikel
Open Access Art:	DEAL (Springer Gold)
Titel eines Journals oder einer Zeitschrift:	Lipids in Health and Disease
Verlag:	Springer
Band:	22
Nummer des Zeitschriftenheftes oder des Kapitels:	1
Datum:	3 Oktober 2023
Institutionen:	Medizin > Lehrstuhl für Innere Medizin I Medizin > Lehrstuhl für Klinische Chemie und Laboratoriumsmedizin
Identifikationsnummer:	Wert Typ 10.1186/s12944-023-01929-6 DOI
Stichwörter / Keywords:	Butyrate, Acetate, Calprotectin, Crohn´s disease, Ulcerative colitis, IBD, Biomarker
Dewey-Dezimal-Klassifikation:	600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin
Status:	Veröffentlicht
Begutachtet:	Ja, diese Version wurde begutachtet
An der Universität Regensburg entstanden:	Ja
Dokumenten-ID:	54788

Vorschau

Bibliographische Daten exportieren

ASCII CitationAtomBibTeXData Cite XMLDataCite XML OAIDublin CoreDublin Core (LZV)EndNoteHTML CitationJSONJSON LDMETSMODSOPENAIREOpenAPCRDF+N-TriplesRDF+N3RDF+XMLReferReference ManagerSimple MetadataXMLxMetaDissPlus

---

Zusammenfassung

Background Urinary 3-indoxyl sulfate levels as well as fecal short chain fatty acid (SCFA) concentrations are surrogate markers for gut microbiota diversity. Patients with inflammatory bowel diseases (IBDs) and patients with primary sclerosing cholangitis (PSC), a disease closely associated with IBD, have decreased microbiome diversity. In this paper, the fecal SCFAs propionate, acetate, ...

Zusammenfassung

Background
Urinary 3-indoxyl sulfate levels as well as fecal short chain fatty acid (SCFA) concentrations are surrogate markers for gut microbiota diversity. Patients with inflammatory bowel diseases (IBDs) and patients with primary sclerosing cholangitis (PSC), a disease closely associated with IBD, have decreased microbiome diversity. In this paper, the fecal SCFAs propionate, acetate, butyrate and isobutyrate of patients with IBD and patients with PSC-IBD and urinary 3-indoxyl sulfate of IBD patients were determined to study associations with disease etiology and severity.
Methods
SCFA levels in feces of 64 IBD patients and 20 PSC-IBD patients were quantified by liquid chromatography with tandem mass spectrometry (LC–MS/MS). Urinary 3-indoxyl sulfate levels of 45 of these IBD patients were analysed by means of reversed-phase liquid chromatography-electrospray ionization-tandem mass spectrometry. Feces of 17 healthy controls and urine of 13 of these controls were analyzed in parallel. These cohorts had comparable sex distribution and age.
Results
Urinary 3-indoxyl sulfate concentrations (normalized to urinary creatinine levels) was increased (P = 0.030) and fecal isobutyrate levels (normalized to dry weight of the stool sample) of IBD patients were decreased (P = 0.035) in comparison to healthy controls. None of the analyzed metabolites differed between patients with Crohn´s disease (CD) and patients with ulcerative colitis (UC). Fecal acetate and butyrate positively correlated with fecal calprotectin (P = 0.040 and P = 0.005, respectively) and serum C-reactive protein (P = 0.024 and P = 0.025, respectively) in UC but not CD patients. UC patients with fecal calprotectin levels above 150 µg/g, indicating intestinal inflammatory activity, had higher fecal acetate (P = 0.016), butyrate (P = 0.007) and propionate (P = 0.046) in comparison to patients with fecal calprotectin levels < 50 µg/g. Fecal SCFA levels of PSC-IBD and IBD patients were comparable.
Conclusions
Current findings suggest that analysis of urinary 3-indoxyl-sulfate as well as fecal SCFAs has no diagnostic value for IBD and PSC-IBD diagnosis or monitoring of disease severity.

---

---

Metadaten zuletzt geändert: 20 Feb 2024 16:03

Nur für Besitzer und Autoren: Kontrollseite des Eintrags

Downloadstatistik

Downloadstatistik

Downloadstatistik

Downloadstatistik

Downloads

Downloads im Monat während des letzten Jahres

Altmetric

Altmetric

Altmetric

Alternative Statistik (altmetrics)

Weitere Literatur (mittels CORE)

Weitere Literatur (mittels CORE)

Weitere Literatur (mittels CORE)

Weitere Literatur (mittels CORE)